~~<i id='B7C071DAAC'><strike id='B7C071DAAC'><tt id='B7C071DAAC'><pre id='B7C071DAAC'></pre></tt></strike></i>~~

Home» explore» leisure time

leisure time

author：leisure time 2025-10-01 20:17:21 Page View：7

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Syphilis numbers in the United States reach record heights
Next article： State Dept. review finds Biden bears some blame for Afghanistan failures

focus

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

Syphilis numbers in the United States reach record heights

Atissuesamplewiththepresenceofnumerous,corkscrew-shaped,darklystainedTreponemapallidumspirochetes,th

Sports medicine is finally prioritizing gender equality

MollyFergusonforSTATWhencyclistAlisonTetrickjoinedthesport’sprofessionalranks,shereceivedtheperkstha

Boston competes with Raleigh

PatGreenhouse/GlobeStaffMORRISVILLE,N.C.—TenminutesfromtheRaleighairport,thefutureofbiotechisunderco